The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Hong Kong Fund Oasis Sues Kobayashi Execs over Beni-Koji Scandal
Hong Kong-based activist investor Oasis Management said on April 7 that it has filed a shareholder lawsuit with the Osaka District Court against Kobayashi Pharmaceutical’s former directors, seeking a total of roughly 13.5 billion yen in damages. Oasis claims that…
To read the full story
Related Article
- Kobayashi Pharma Scraps Medium-Term Biz Plan Due to Beni-Koji Scandal
February 12, 2025
- Kobayashi Pharma to Revamp Management under New President
January 22, 2025
- Puberulic Acid Determined as Cause of “Beni-Koji” Health Damages
September 19, 2024
- Kobayashi Pharma Replaces Management after Beni-Koji Scandal
July 24, 2024
- More Unexpected Substances in Kobayashi’s Beni-Koji Supplements: MHLW
April 22, 2024
- Fanconi Syndrome Found in Majority of Health Damages Tied to Beni-Koji Supplements
April 10, 2024
- Kobayashi Factory Inspected over Beni-Koji Health Issue
April 1, 2024
- “Puberulic Acid” in Beni-Koji Supplements; Kobayashi Wants to Keep Healthcare Biz
April 1, 2024
- Beni-Koji Issue: MHLW Requests Self-Inspections to Purchasers of Kobayashi’s Red Rice Yeast
March 29, 2024
- Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
March 28, 2024
- One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
- Kobayashi’s Beni Koji Health Damage Reports Trigger Knock-On Recalls
March 27, 2024
- Hospitalized Cases Tied to Kobayashi Pharma’s Supplements Now Up to 26
March 26, 2024
- Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
BUSINESS
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
- Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…